MA-NUMARES
21.1.2021 12:02:09 CET | Business Wire | Press release
Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the numares brand AXINON® .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005438/en/
Based on a longstanding collaboration between the two companies, the agreement creates a combination of numares ’ expertise in leveraging metabolomics for software-based diagnostics with world-leading nuclear magnetic resonance (NMR) technology from Bruker. This leads to more rapid, accurate and personalized information about the severity and progress of diseases.
This collaboration will support the ongoing transition of AXINON® platform from research into routine clinical use, and makes it available to all patients as an affordable, day-to-day diagnostic standard. Two years ago, numares started a collaboration with US-based Mayo Clinic for joint diagnostic test development using metabolomics and NMR. The collaboration of numares and Bruker now marks a further milestone in the numares vision to bring these technologies into routine diagnostics.
The AXINON® platform based on NMR spectroscopy is a non-invasive technique that is uncovering new potential for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer. The numares system measures various metabolic patterns and applies artificial intelligence (AI) to cluster and translate the results into clinical diagnosis. This rich source of information gives healthcare professionals new insight into disease management, and gives patients fast access to the right treatment. Likewise, the AXINON® platform also supports disease risk prediction, paving the way to new developments in precision medicine and companion diagnostics.
Dr. Volker Pfahlert, Director of the Board of numares says: “Our agreement will help to expand the exciting potential of NMR technology, long established in academic and clinical research, to the clinical diagnostics industry where numares already has a strong customer base. It paves the way for market entry of NMR diagnostics under FDA regulations, a prerequisite to make it accessible to all patients as day-to-day applications in routine clinical diagnostics. It will support numares to better utilize its test development in several indications such as kidney disease, liver disease or neurological disorders.”
Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied, Clinical and Industrial division comments: “The pandemic of 2020 has brought unimaginable challenges on a global scale. With the world’s spotlight sharply focused on the healthcare industry, our business has accelerated to develop the technology and diagnostic solutions that is desperately needed. The innovations born out of this demand have paved the way for future, highly advanced new product developments. Partnering with numares will bring our technology to the frontline healthcare industry, where it is most needed. NMR technology delivers the robust and reproducible results needed to support the advanced AI modelling techniques deployed by numares . Together, our complementary technologies offer a powerful arm in the fight against disease of the future.”
Co-CEO and President of numares Group Corp. Winton Gibbons concludes: “This agreement is a further important step in the commercialization of our products in the US. With GFRNMR we will soon launch a novel blood test to help identify and quantify impaired kidney function in patients with this more accurate, easy-to-access, and affordable diagnostic standard.”
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005438/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release
Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release
Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and
Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release
Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
